返回 
加入收藏
缬沙坦联合氢氯噻嗪治疗慢性肾脏病合并肾性高血压的临床观察
x
请在关注微信后，向客服人员索取文件
| 篇名： | 缬沙坦联合氢氯噻嗪治疗慢性肾脏病合并肾性高血压的临床观察 |
| TITLE： | |
| 摘要： | 目的：观察缬沙坦联合氢氯噻嗪治疗慢性肾脏病合并肾性高血压的临床疗效和安全性。方法： 156例慢性肾脏病合并肾性高血压患者随机分为对照组和观察组，每组78例。对照组患者给予氢氯噻嗪片25 mg，口服，每日1次，观察组患者在对照组治疗基础上加服缬沙坦胶囊80 mg，每日1次。两组疗程均为4周。观察并比较两组患者临床疗效，治疗前后收缩压（SBP）、舒张压（DBP）、肾小球滤过率（GFR）、24 h尿蛋白定量、血肌肝（Scr）、血尿素氮（BUN）水平及不良反应发生情况。结果：观察组患者临床总有效率显著高于对照组，差异有统计学意义（85.90％ vs. 64.10％，P＜0.05）。治疗前，两组患者SBP、DBP、GFR、24 h尿蛋白定量、Scr及BUN比较，差异均无统计学意义（P＞0.05）。治疗后，两组患者SBP、DBP、24 h尿蛋白定量、Scr及BUN水平显著低于同组治疗前，且观察组显著低于对照组，GFR显著高于同组治疗前，且观察组显著高于对照组，差异均有统计学意义（P＜0.05）。两组患者不良反应发生率比较，差异无统计学意义（P＞0.05）。结论： 缬沙坦联合氢氯噻嗪治疗慢性肾脏病合并肾性高血压疗效较好，可以显著改善患者血压和肾功能，安全性亦较好。 |
| ABSTRACT： | OBJECTIVE： To observe clinical efficacy and safety of valsartan combined with hydrochlorothiazide in the treatment of chronic renal disease complicated with hypertension. METHODS： A total of 156 chronic kidney disease patients with renal hypertensive were randomly divided into control group and observation group with 78 cases in each group. Control group was given hydrochlorothiazide tablets 25 mg orally，once a day. Observation group was additionally given valsartan capsule 80 mg orally，once a day， on the basis of control group. Treatment course of 2 groups lasted for 4 weeks. Clinical efficacies of 2 groups were observed and compared， and the levels of SBP， DBP， GFR， 24 h urine protein quantification， Scr and BUN were observed before and after treatment. The occurrence of ADR was recorded. RESULTS： After treatment， total response rate of observation group was significantly higher than that of control group， with statistical significance （85.90％ vs. 64.10％，P＜0.05）. Before treatment， there was no statistical significance in SBP， DBP， GFR， 24 h urine protein quantification， Scr and BUN between 2 groups （P＞0.05）. After treatment， SBP，DBP，24 h urine protein quantification，Scr and BUN of 2 groups were significantly lower than before treatment，the observation group was significantly lower than the control group， GFR was significantly higher than before treatment， the observation group was significantly higher than that of control group， with statistical significance （P＜0.05）. There was no statistical significance in the incidence of ADR between 2 groups （P＞0.05）. CONCLUSIONS： Valsartan combined with hydrochlorothiazide show good therapeutic efficacy for chronic renal disease complicated with hypertension， and can significantly improve blood pressure and renal function with good safety. |
| 期刊： | 2017年第28卷第33期 |
| 作者： | 栾森，邓尧 |
| AUTHORS： | LUAN Sen，DENG Yao |
| 关键字： | 缬沙坦；氢氯噻嗪；慢性肾脏病；肾性高血压；肾功能 |
| KEYWORDS： | Valsartan； Hydrochlorothiazide； Chronic renal disease； Renal hypertension； Renal function |
| 阅读数： | 239 次 |
| 本月下载数： | 2 次 |
* 注：未经本站明确许可，任何网站不得非法盗链资源下载连接及抄袭本站原创内容资源!在此感谢您的支持与合作！
